| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | 20E |
| Uniprot No | P49770 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-351aa |
| 氨基酸序列 | MPGSAAKGSELSERIESFVETLKRGGGPRSSEEMARETLGLLRQIITDHRWSNAGELMELIRREGRRMTAAQPSETTVGNMVRRVLKIIREEYGRLHGRSDESDQQESLHKLLTSGGLNEDFSFHYAQLQSNIIEAINELLVELEGTMENIAAQALEHIHSNEVIMTIGFSRTVEAFLKEAARKRKFHVIVAECAPFCQGHEMAVNLSKAGIETTVMTDAAIFAVMSRVNKVIIGTKTILANGALRAVTGTHTLALAAKHHSTPLIVCAPMFKLSPQFPNEEDSFHKFVAPEEVLPFTEGDILEKVSVHCPVFDYVPPELITLFISNIGGNAPSYIYRLMSELYHPDDHVL |
| 预测分子量 | 66.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于20E重组蛋白的3篇参考文献示例(注：内容为模拟概括，仅供参考)：
1. **《Functional Characterization of 20E Recombinant Protein in Insect Molting Regulation》**
- 作者：T.R. Smith et al.
- 摘要：研究通过重组表达20E结合蛋白(EcR/USP复合体)，解析其在昆虫蜕皮激素信号通路中的作用，证实重组蛋白在体外能特异性结合20E并激活下游基因表达。
2. **《Structural Analysis of 20E-Binding Recombinant Protein Complex》**
- 作者：L. Wang & J. Chen
- 摘要：利用X射线晶体学技术解析20E重组受体蛋白的三维结构，揭示了激素结合域的关键氨基酸残基，为设计靶向调控剂提供结构基础。
3. **《Application of Recombinant 20E Protein in Drug Screening》**
- 作者：M. Rodriguez et al.
- 摘要：开发基于20E重组蛋白的高通量药物筛选平台，筛选出多种可调控蜕皮激素通路的小分子化合物，潜在应用于农业害虫防治。
4. **《Role of Recombinant 20E Protein in Drosophila Development》**
- 作者：K. Ito et al.
- 摘要：通过果蝇模型验证重组20E蛋白对幼虫蜕皮和蛹化的调控功能，发现其剂量依赖性激活特定发育基因的表达。
(注：以上文献名称及内容为虚构示例，实际文献需通过学术数据库检索。)
The 20E recombinant protein, often discussed in the context of COVID-19 vaccine development, represents a key component of subunit vaccine platforms designed to combat SARS-CoV-2 variants. Recombinant protein vaccines utilize genetically engineered viral antigens—commonly the spike (S) protein or its receptor-binding domain (RBD)—to elicit immune responses without using live viruses. The "20E" designation may refer to specific mutations or lineage adaptations (e.g., the 20E (EU1) variant first identified in Spain in mid-2020), but in recombinant protein contexts, it often denotes engineered antigens tailored to enhance immunogenicity or target emerging variants.
These proteins are produced by inserting viral antigen-encoding genes into expression systems (e.g., insect cells, yeast, or mammalian cells), followed by purification. For example, Novavax’s NVX-CoV2373 vaccine employs a recombinant spike protein nanoparticle formulated with a saponin-based adjuvant (Matrix-M). The approach prioritizes safety (no live virus handling), stability, and scalability, making it suitable for global distribution, particularly in low-resource settings.
As SARS-CoV-2 evolved, recombinant protein platforms demonstrated flexibility in updating antigen designs to match circulating variants, such as Omicron sublineages. The 20E-based constructs (if lineage-aligned) would incorporate mutations like D614G or others to improve antibody recognition. Recent efforts focus on multivalent or pan-coronavirus vaccines, leveraging recombinant technology to address viral diversity. Clinical trials have shown recombinant protein vaccines to be well-tolerated, with robust neutralizing antibody and T-cell responses, though real-world efficacy depends on antigenic match and adjuvant synergy. This platform remains pivotal for pandemic preparedness and routine immunization strategies.
×
